You are not logged in.

Novel approaches to treatment of leiomyosarcomas

Collins, Ian and Thomas, DM 2011, Novel approaches to treatment of leiomyosarcomas, Current oncology reports, vol. 13, no. 4, pp. 316-322, doi: 10.1007/s11912-011-0173-0.

Attached Files
Name Description MIMEType Size Downloads

Title Novel approaches to treatment of leiomyosarcomas
Author(s) Collins, IanORCID iD for Collins, Ian orcid.org/0000-0001-6936-0942
Thomas, DM
Journal name Current oncology reports
Volume number 13
Issue number 4
Start page 316
End page 322
Total pages 7
Publisher Springer
Place of publication Berlin, Germany
Publication date 2011-08
ISSN 1523-3790
Keyword(s) Sarcoma
Leiomyosarcoma
p53 mutation
Poly ADP-Ribose Polymerase (PARP) inhibitors
Angiogenesis Inhibitors
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Deoxycytidine
administration
dosage
Doxorubicin
Enzyme Inhibitors
Humans Ifosfamide
drug therapy
genetics
therapeutic use
Summary Soft tissue sarcomas are rare tumors and include subtypes with variable clinical, pathological, and genetic characteristics, including leiomyosarcoma. Current chemotherapy options include the use of doxorubicin, ifosfamide, gemcitabine and docetaxel, and trabectedin, but these have poor response rates in the metastatic setting. While some targeted therapies with tyrosine kinase inhibitors have shown promise, there is a clear need for novel, targeted strategies for this enigmatic form of soft-tissue sarcoma. The genomic instability and multiple, complex karyotypic abnormalities of leiomyosarcomas is a potential for therapy with agents with proven activity in other cancers with genomic instability, such as BRCA-related breast or ovarian cancer. There are few pathways affected in leiomyosarcoma that suggest obvious opportunities, but poly ADP-ribose polymerase (PARP) inhibitors hold promise. This article outlines current therapeutic options available and undergoing study, as well as explores the rationale for the study of PARP inhibitors in leiomyosarcomas, with or without chemotherapy.
Language eng
DOI 10.1007/s11912-011-0173-0
Field of Research 111202 Cancer Diagnosis
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1.1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2011, Springer Science+Business Media
Persistent URL http://hdl.handle.net/10536/DRO/DU:30075056

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in TR Web of Science
Scopus Citation Count Cited 3 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 4 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Fri, 14 Aug 2015, 08:58:20 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.